2. Cancer
  3. Cancer Targeted Therapy

Cancer Targeted Therapy

Cancer targeted therapy is the foundation of precision medicine; it uses drugs or other substances to target specific genes and proteins that control cancer cells’ growth, division and spreading. Compared to traditional chemotherapy drugs, targeted-drugs can specifically act on cancer cells with high efficacy without damaging normal cells. Drugs used in cancer targeted therapy mainly includes small molecules and macromolecules (e.g., monoclonal antibodies), which can target cancer cells and constituents in the tumor microenvironment to activate the immune system. Anti-angiogenesis drugs, such as those targeting vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), transforming growth factor (TGF)-α, TGF-β, Tumor necrosis factor (TNF)-α, and platelet-derived endothelial growth factor (PDGFR) inhibit the proliferation and metastasis of cancer cells. In recent years, the proportion of antibody drugs in cancer treatment has gradually become prominent. Antibody-drug conjugates (ADCs) are a new type of targeted drugs that are composed of monoclonal antibody, cytotoxic drug and linker. ADCs can deliver drugs to tumor cells and minimize the toxicity to normal tissues. Proteolysis-targeting chimera (PROTAC) is a useful technology for targeted protein degradation. PROTAC exploits the ubiquitin-proteasome system and forms a ternary complex with a hijacked E3 ubiquitin ligase and target protein, leading to polyubiquitination and degradation of the target protein.

Targeted therapy is a useful strategy in treatment of cancer either alone or in combination with standard chemotherapy. At present, targeted therapy has proved significant clinical success in the treatment of many types of cancer, including breast cancer, colorectal cancer, leukemia, ovarian cancer and lung cancer.

Cancer Targeted Therapy Related Products (34066):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161640
    E3 Ligase Ligand-linker Conjugate 109 2911613-55-1
    E3 Ligase Ligand-linker Conjugate 109 is a E3 ligase ligand-linker conjugate, used for the the synthesis of PROTAC SOS1 degrader (HY-161636).
    E3 Ligase Ligand-linker Conjugate 109
  • HY-108963
    LY 170198 99682-33-4
    LY 170198 is a protein kinase C inhibitor and a LTD4 antagonist. LY 170198 is promising for research of tumor promotion, oncogene activation, protein phosphorylation, feedback mechanisms in signal transduction and cellular responses to growth factors.
    LY 170198
  • HY-149568
    Thalidomide-5-O-C11-NH2 hydrochloride
    Thalidomide-5-O-C11-NH2 hydrochloride is the Thalidomide (HY-10984)-based cereblon ligand used in the recruitment of CRBN protein.Thalidomide-5-O-C11-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTACs.
    Thalidomide-5-O-C11-NH2 hydrochloride
  • HY-N12820
    3-O-6-Deoxy-3-O-methyl-β-D-allopyranosyl-(1→4)-β-D-oleandropyranosyl-tenacigenin C 863767-80-0
    3-O-6-Deoxy-3-O-methyl-β-D-allopyranosyl-(1→4)-β-D-oleandropyranosyl-tenacigenin C can be isolated from Alocasia cucullata (Lour.) G. Don. 3-O-6-Deoxy-3-O-methyl-β-D-allopyranosyl-(1→4)-β-D-oleandropyranosyl-tenacigenin C has moderate tumor cells inhibitory activity against MGC-803 and HT-29 cells with IC50 values of 45.6 and 28.4 μg/mL, respectively.
    3-O-6-Deoxy-3-O-methyl-β-D-allopyranosyl-(1→4)-β-D-oleandropyranosyl-tenacigenin C
  • HY-13780R
    Vinblastine (sulfate) (Standard) 143-67-9
    Vinblastine (sulfate) (Standard) is the analytical standard of Vinblastine (sulfate). This product is intended for research and analytical applications. Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR with an IC50 of 8.9 μM.
    Vinblastine (sulfate) (Standard)
  • HY-164374
    AK963/40708899 445007-59-0
    AK963/40708899 is a potent PAK1 inhibitor. AK963/40708899 suppresses the proliferation of human gastric cancer cells by downregulation of PAK1-NF-κB-cyclinB1 pathway. AK963/40708899 induces cell cycle arrest at G2 phase and reduces the migration and invasion. AK963/40708899 inhibits the formation of filopodia and promots cell adhesion which in turn inhibits invasive potential of gastric cells by negatively regulating PAK1-LIMKl-cofilin and PAK1-ERK-FAK pathways.
    AK963/40708899
  • HY-B0253A
    Piroxicam olamine 85056-47-9
    Piroxicam olamine (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.
    Piroxicam olamine
  • HY-156300
    Me-Tet-PEG4-NH2 2055646-21-2
    Me-Tet-PEG4-NH2 is an ADC Linker containing 4 PEG units. Me-Tet-PEG4-NH2 can use its own Tetrazine group to undergo a specific inverse electron demand Diels-Alder reaction (iEDDA) with compounds with TCO groups.
    Me-Tet-PEG4-NH2
  • HY-158431
    (S,R,S)-AHPC-Me-8-bromooctanoic acid 2638512-58-8
    (S,R,S)-AHPC-Me-8-bromooctanoic acid is an E3 ligase ligand-linker conjugate, and can be used for synthesis of PROTAC CYP1B1 degrader-2 (HY-158429).
    (S,R,S)-AHPC-Me-8-bromooctanoic acid
  • HY-W843265
    PIN1 inhibitor 6 637325-53-2
    PIN1 inhibitor 6 (compound 38) is a Pin1 inhibitor. PIN1 inhibitor 6 can be utilized in cancer research.
    PIN1 inhibitor 6
  • HY-137628
    Sp-8-PIP cAMP 156816-35-2
    Sp-8-PIP cAMP sodium is a non-corresponding isomer of 8-Piperidino-cAMP. 8-Piperidino-cAMP binds with high affinity to site A of the regulatory subunit of cAMP-dependent protein kinase type I (AI). Sp-8-PIP cAMP sodium can be used as an antagonist of cAMP-induced activation.
    Sp-8-PIP cAMP
  • HY-159093
    Antitumor agent-178
    GSCs-IN-1 (compound 4 h) is a potent and selective GSCs inhibitor. GSCs-IN-1 has the potential for the research of cancer.
    Antitumor agent-178
  • HY-I0678R
    Regorafénib N-oxyde (M2) (Standard) 835621-11-9
    Quinocetone (Standard) is the analytical standard of Quinocetone. This product is intended for research and analytical applications. Quinocetone is a potent synthetic antimicrobial agent that is used for improving the feed efficiency and controlling dysentery in food-producing animals.
    Regorafénib N-oxyde (M2) (Standard)
  • HY-N15264
    Azaspirene 461644-34-8
    Azaspirene ((-)-Azaspirene) is an angiogenesis and Raf-1 activation inhibitor isolated from the fungus Neosartorya sp. Azaspirene inhibits vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) migration and Raf-1 activation, but has no effect on the activation of kinase insert domain-containing receptor/fetal liver kinase 1 (VEGF receptor 2).
    Azaspirene
  • HY-P991120
    Balertatug 3010940-29-8
    Balertatug is a human IgG1K antibody targeting CD70. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001).
    Balertatug
  • HY-13038AR
    Fostamatinib (Standard) 901119-35-5
    Fostamatinib (Standard) is the analytical standard of Fostamatinib. This product is intended for research and analytical applications. Fostamatinib (R788) is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM).
    Fostamatinib (Standard)
  • HY-A0006R
    Pentostatin (Standard) 53910-25-1
    Pentostatin (Standard) is the analytical standard of Pentostatin. This product is intended for research and analytical applications. Pentostatin (CI-825; Deoxycoformycin) is an irreversible inhibitor of adenosine deaminase with Ki of 2.5 pM.
    Pentostatin (Standard)
  • HY-165164
    Methotrexate-alpha-alanine 116819-28-4
    Methotrexate-alpha-alanine is a prodrug for activation by enzyme-monoclonal antibody conjugates. Methotrexate-alpha-alanine shows cytotoxicity.
    Methotrexate-alpha-alanine
  • HY-168892
    LC3B recruiter 2 380636-64-6
    LC3B recruiter 2 (34R) is an LC3B recruiter and a component of the autophagy-lysosome pathway degradation system (ATTEC, Autophagy-Tethering Compounds), which directly binds to LC3B. LC3B recruiter 2 binds to CDK9 inhibitor SNS-032 (HY-10008) through a linker, forming an ATTEC that targets the degradation of the CDK9 and Cyclin T1 complex (with inhibitory effects on both). Therefore, LC3B recruiter 2 exerts activity through the LC3B-dependent autophagy-lysosome pathway, interfering with the cell cycle of cancer cells, thus exhibiting antitumor activity.
    LC3B recruiter 2
  • HY-N12414
    Apicularen A 220757-04-0
    Apicularen A is a macrolide isolated from the mucoid bacterium Chondrosporium spp. Apicularen A is also a highly selective inhibitor of vesicular ATPase.
    Apicularen A